LENZ Therapeutics, Inc. SEC filings LENZ

LENZ Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to Mar 19, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations, exit or restructuring costs, officer or director change). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 12, 2026
DEFA14A Additional proxy material Apr 28, 2025 —
DEF 14A Proxy statement Apr 28, 2025 Jun 10, 2025
DEFA14A Additional proxy material Jun 6, 2023 —
DEF 14A Proxy statement Jun 6, 2023 Jul 19, 2023
DEFA14A Additional proxy material Apr 29, 2022 —
DEF 14A Proxy statement Apr 29, 2022 Jun 21, 2022

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
LENZ (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Solana Beach, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1815776
Former names
Graphite Bio, Inc. (until Mar 19, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.